For those with middle, HS, or kids in college. Best 10 minutes you can spend today, tomorrow, next year is Bill’s TED talk

The Chase begins in earnest —LMAO $ABVX

Ottawa: “Hot team. Great goalie. Definitely going seven.” 4-0, CAR. Philly: “Hot team. Great goalie. Definitely going seven.” 4-0, CAR. MTL: “Hot team. Great goalie. Definitely going seven.” 4-1, CAR. Vegas: “Hot team. Great goalie. Definitely going seven.”

I attended a gay orgy once and it was less homosexual than this car

For those that don’t closely follow motorsports racing. The Indy 500 finish was one for the history books and closest in history. For my biotech driver friends hats off to the great driving. CLOSEST Finish in Indy 500 History | 2026 INDYCAR youtu.be/Ubt9vnioGyA?si=Bsxd… via @YouTube

RT @dlacalle_IA: The US does not need to bow to Iran’s threats. Every day, the “Hormuz weapon” loses power as American oil production, exp…

$PCVX - double position - thanks for the sub $50 shares.

Commercial late clinical/registrational = ~91% Does not mean they never invest early. Kymera, Revolution, Stoke, AbCellera, Nurix, Bicycle, and others show they will back platforms early. But the larger dollar pattern is: 1. Enter early or mid-stage when biology is exceptional 2. Increase after human proof-of-concept 3. Hold or concentrate pivotal/commercial phase 4. Let winners become massive portfolio weights

Daughter’s 1st poster presentation! Effects of cardiomyocyte-specific knockout of unc45b on zebrafish cardiac muscle structure and function. Present May 2nd

𝐖𝐡𝐚𝐫𝐭𝐨𝐧 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞: Irene Rombel, Co-founder and CEO of BioCurie discuss AI in biotech and keeping manufacturing of advanced therapies in the United States.

Good lord - this may be one of the worst calls in the playoffs Seeler drags the stick of Martinook into his own face..

Dave is right - USVC yet another grift in the world of retail-accessible VC. I went through the 56-page prospectus and its even worse than the tweet suggests: 1. Fee stack: 3.61% gross annual expense ratio, capped net at 2.50%. Underlying SPVs/VC funds charge another 1–2.5% mgmt 20–30% carry on top. You're paying 3 layers of fees before any return hits your account. 2. The prospectus states twice, verbatim: "The Investment Adviser has no previous experience managing a closed-end, registered investment company." The adviser was formed Dec 2023 and rebranded from "Strawberry Tree Management" to "AngelList Asset Management" last November. 3. Portfolio manager Ankur Nagpal is compensated on AUM growth, not performance. Straight from the prospectus: his Carry acquisition earnout "includes contingent payments tied to USVC's growth in assets under management." Textbook non-traded REIT incentive structure. 4. AngelList gets paid three times on the same dollar: • 1% advisory fee to AngelList Asset Management • Up to 5% of profits to Platform Advisor LLC (AngelList affiliate) • Fund admin fees to Belltower Fund Group (AngelList affiliate) 5. NAV is sponsor-marked - the adviser is its own "valuation designee." Prospectus disclaimer: "Fair value prices are necessarily subjective in nature…no assurance that such a price will be at or close to the price at which the security is next quoted or next trades." 6. "5% quarterly redemptions" is marketing. Reality: Board can cancel any offer, can offer less than 5%, can repurchase at a discount to NAV, and oversubscribed offers prorate. Straight from the doc: "Shareholders should not rely on being able to tender the full amount—or any—of their Shares." 7. Naval frames it as "VC for everyone." The prospectus describes a non-traded CEF with sponsor-marked NAV, AUM-linked manager comp, three layers of affiliate fees, and gated discretionary liquidity. Retail doesn't need access to private markets this badly.

I have arrived !!!

Cell and gene therapy developers shouldn’t have to guess about what safety studies FDA wants to see. Today, FDA issued clear draft guidance that will save developers millions of dollars and years of effort, accelerating treatments to patients. Every effort to move more efficiently here is worth it.

Iran's Foreign Minister.   "For a period of two weeks, safe passage through the Strait of Hormuz will be possible via coordinationwith Iran's Armed Forces and with due consideration of technical limitations."   Trump's condition: complete, immediate, safe opening.   Iran's acceptance: managed passage, coordinated through their military, subject to limitations that they define.   FYI- not the same thing Mr Market might be a bit optimistic here

rome thought it was spreading civilization. britain thought it was spreading civilization. america thinks it's spreading freedom. none of them were lying. that's the scary part. every empire is the hero of its own story right up until the last chapter.

It looks like the White House is finally taking US-China biotech competition seriously. The FDA is putting forward an expedited IND pathway that would shorten time to first-in-human. Overdue, but good news for American biotech.

Biotech IPO Cohorts: Capital, Time & Maturity (2017-2026) **Biotech IPOs have evolved from ~$80–100M, ~6-year, Phase 1 companies achieving ~1.5–2.0x re-ratings to ~$500M pvt raisings, ~11-year, Phase 2/3 companies accessing public markets with minimal valuation uplift

$PRTC --PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers - businesswire.com/news/home/2…